Anti-RAGE and Aβ immunoglobulin levels are related to dementia level and cognitive performance

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 64, Issue 2, 2009, Pages 264-271

  Wilson, Jennifer S ^a   Mruthinti, Shyamala ^b,c   Buccafusco, Jerry J ^b,c   Schade, Rosann F ^b,c   Mitchell, Meghan B ^a   Harrell, Dean U ^c   Gulati, Nidhi K ^c,d   Miller, L Stephen ^a,e  

^a University of Georgia ^*  (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d Georgia War Veterans Nursing Home   (United States)

^e UNIVERSITY OF GEORGIA   (United States)

Author keywords

A ; Alzheimer's disease; Biomarker; Cognition; Dementia; Immunoglobulin; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR ANTIBODY; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42] ANTIBODY; IMMUNOGLOBULIN ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; IMMUNOGLOBULIN G; IMMUNOGLOBULIN RECEPTOR;

AGED; ALZHEIMER DISEASE; APTITUDE TEST; ARTICLE; COGNITION; DEMENTIA; DISEASE ASSOCIATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LANGUAGE; MAJOR CLINICAL STUDY; MEMORY; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROTEIN PURIFICATION; SCORING SYSTEM; SHORT TERM MEMORY; AGE; AGING; BLOOD; COGNITIVE DEFECT; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE COURSE; DRUG ANTAGONISM; FEMALE; HOSPITALIZATION; IMMUNOLOGY; MALE; METABOLISM; MULTIVARIATE ANALYSIS; PHYSIOLOGY; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; STATISTICAL MODEL;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; COGNITION DISORDERS; COHORT STUDIES; DEMENTIA; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN G; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; PROBABILITY; PROGNOSIS; RECEPTORS, IMMUNOLOGIC; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 64949170901     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/gln002     Document Type: Article

References (38)

1. Kinsella K, Velkoff V, U.S. Census Bureau. An Aging World:2001 (Series P95/01-1). Washington, DC:U.S. Government Printing Office.
2. Anderson G, Hussey P. Population aging: a comparison among industrialized countries. Health Aff. 2000;19:191-203.
3. Centers for Disease Control. Public health and aging: trends in aging - United States and worldwide. MMWR. 2003;52:101-106.
4. Licastro F, Candore G, Lio D, et al. Innate immunity and inflammation in ageing: a key to understanding age-related diseases. Immun Ageing. 2005;2:8. (Pubitemid 44848803)
5. Benzi G, Moretti A. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? Eur J Pharmacol. 1998;346:1-13. (Pubitemid 28197082)
6. Wisniewski T, Ghiso J, Frangione B. Biology of Abeta amyloid in Alzheimer's disease. Neurobiol Dis. 1997;4:313-328. (Pubitemid 28018660)
7. Irizarry M, McNamara N, Fedorchak K, Hsiao K, Hyman B. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol. 1997;56:965-973. (Pubitemid 27386126)
8. Yan S, Zhu H, Fu J, et al. Amyloid-beta peptide - receptor for advanced glycation end product interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer's disease. Proc Natl Acad Sci USA. 1997;94:5296-5301. (Pubitemid 27214777)
9. Arancio O, Zhang H, Chen X, et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. Eur Mol Biol Org J. 2004;23:4006-4105. (Pubitemid 39472430)
10. Chaney M, Stine W, Kokjohn T, et al. RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochem Biophys Acta. 2005;1741:199-205. (Pubitemid 40825005)
11. Lue L-F, Walker D, Brachova L, et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol. 2001;171:29-45. (Pubitemid 32848443)
12. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-177. (Pubitemid 29327547)
13. Hyman B, Smith C, Buldyrev I, et al. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann Neurol. 2001;49:808-810.
14. Lopez O, Rabin B, Huff F, Rezek D, Reinmuth O. Serum autoantibodies in patients with Alzheimer's disease and vascular dementia and in nondemented control subjects. Stroke. 1992;23:1078-1083.
15. Nath A, Hall E, Tuzova M, et al. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med. 2003;3:29-39. (Pubitemid 37070580)
16. Dodel R, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004;75:1472-1474. (Pubitemid 39279821)
17. Hock C, Konietzko U, Streffer J, et al. Antibodies against betaamyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38:547-554. (Pubitemid 36645030)
18. Zhang Y, Pardridge W. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol. 2001;114:168-172. (Pubitemid 32184738)
19. Bouras C, Riederer B, Kovari E, Hof P, Giannakopoulos P. Humoral immunity in brain aging and Alzheimer's disease. Brain Res Rev. 2005;48:477-487. (Pubitemid 40731511)
20. Van Reekum R, Simard M, Cohen T. The prediction and prevention of Alzheimer's disease - towards a research agenda. J Psychiatry Neurosci. 1999;24:413-430. (Pubitemid 30022156)
21. Mruthinti S, Hill W, Swamy-Mruthinti S, Buccafusco J. Relationship between the induction of RAGE cell-surface antigen and the expression of amyloid binding sites. J Mol Neurosci. 2002;20:17-26. (Pubitemid 38146975)
22. Mruthinti S, Buccafusco J, Hill W, et al. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding ABeta and RAGE peptides. Neurobiol Aging. 2004;25:1023-1032. (Pubitemid 38798064)
23. Thomas M, Tsalamandris C, MacIsaac R, et al. Low molecular weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. Kidney Int. 2004;66:1167-1172. (Pubitemid 39121024)
24. Wautier L, Wautier MP, Schmidt AM, et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA. 1994;91:7742-7746. (Pubitemid 24238261)
25. Merlin CT, Josephin MF, Mark EC. Advanced glycation end products and diabetic nephropathy. Am J Ther. 2005;12:562-572. (Pubitemid 41689757)
26. Verbeke P, Perichon M, Borot-Laloi C, Schaeverbeke J, Bakala H. Accumulation of advanced glycation endproducts in the rat nephron: link with circulating AGEs during aging. J Histochem Cytochem. 1997;45:1059-1068. (Pubitemid 27347336)
27. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.
28. Randolph C. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). San Antonio, Tex: The Psychological Corporation; 1998.
29. Randolph C, Tierney M, Mohr E, Chase T. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20:310-319. (Pubitemid 28539551)
30. Verhaeghen P, Salthouse T. Meta-analyses of age-cognition relations in adulthood: estimates of linear and non-linear age effects and structural models. Psychol Bull. 1997;122:231-249. (Pubitemid 127705586)
31. Hughes C, Berg L, Danziger W, Coben L, Martin R. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.
32. Randolph C. Repeatable Battery for the Assessment of Neuropsychological Status. Technical Report #1: unpublished Post-publication Update. 2005.
33. Dickerson F, Boronow J, Stallings C, Origoni A, Ruslanova I, Yolken R. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch Gen Psychiatry. 2003;60:466-472. (Pubitemid 36539055)
34. Moser DJ, Hoth KF, Robinson RG, et al. Blood vessel function and cognition in elderly patients with atherosclerosis. Stroke. 2004;35:369-372.
35. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267:4998-5004.
36. Sasaki N, Toki S, Chowei H, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res. 2001;888:256-262. (Pubitemid 32058790)
37. Mruthinti S, Schade R, Harrell D, et al. Autoimmunity in Alzheimer's disease as evidenced by plasma immunoreactivity against RAGE and Abeta42: complication of diabetes. Curr Alzheimer Res. 2006;3:229-235. (Pubitemid 43988136)
38. Crystal HA, Dickson DW, Sliwinski MJ, et al. Pathological markers associated with normal aging and dementia in the elderly. Ann Neurol. 1993;34:566-573.